Related references
Note: Only part of the references are listed.Efficacy of Systemic Morpholino Exon-Skipping in Duchenne Dystrophy Dogs
Toshifumi Yokota et al.
ANNALS OF NEUROLOGY (2009)
Hydrodynamic Limb Vein Injection of Adeno-Associated Virus Serotype 8 Vector Carrying Canine Myostatin Propeptide Gene into Normal Dogs Enhances Muscle Growth
Chunping Qiao et al.
HUMAN GENE THERAPY (2009)
Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy?
Michael D. Puchalski et al.
INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING (2009)
Transduction Efficiency and Immune Response Associated With the Administration of AAV8 Vector Into Dog Skeletal Muscle
Sachiko Ohshima et al.
MOLECULAR THERAPY (2009)
Hematopoietic cell transplantation provides an immune-tolerant platform for myoblast transplantation in dystrophic dogs
Maura H. Parker et al.
MOLECULAR THERAPY (2008)
Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer
Bo Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products
K. Yuasa et al.
GENE THERAPY (2007)
Morpholino oligomer -: Mediated Exon skipping averts the onset of dystrophic pathology in the mdx mouse
Sue Fletcher et al.
MOLECULAR THERAPY (2007)
Managing Duchenne muscular dystrophy - The additive effect of spinal surgery and home nocturnal ventilation in improving survival
Michelle Eagle et al.
NEUROMUSCULAR DISORDERS (2007)
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch et al.
NATURE (2007)
Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy
Zejing Wang et al.
HUMAN GENE THERAPY (2007)
Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs
Maurilio Sampaolesi et al.
NATURE (2006)
Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD
G. McClorey et al.
GENE THERAPY (2006)
Dystrophic heart failure blocked by membrane sealant poloxamer
S Yasuda et al.
NATURE (2005)
Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices
M Vatta et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
P Gregorevic et al.
NATURE MEDICINE (2004)
Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs
C Dell'Agnola et al.
BLOOD (2004)
Tissue Doppler imaging detects early asymptomatic myocardial abnormalities in a dog model of Duchenne's cardiomyopathy
V Chetboul et al.
EUROPEAN HEART JOURNAL (2004)
Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer
M Cerletti et al.
GENE THERAPY (2003)
The heart in human dystrophinopathies
J Finsterer et al.
CARDIOLOGY (2003)
Functional improvement of dystrophic muscle by myostatin blockade
S Bogdanovich et al.
NATURE (2002)
A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle
AP Weir et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog and man
JM Grindel et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2002)
Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy
M Vatta et al.
LANCET (2002)
Share Paper
